Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1133

1.

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.

Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N.

AIDS. 2006 Aug 1;20(12):1613-9. Erratum in: AIDS. 2006 Aug 22;20(13):1790.

PMID:
16868442
2.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
3.
4.
5.

Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.

PMID:
16044002
6.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
7.

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.

Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.

AIDS. 2006 May 12;20(8):1117-23.

PMID:
16691062
8.

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M; Swiss HIV Cohort Study Group.

Arch Intern Med. 2003 Oct 13;163(18):2187-95.

PMID:
14557216
9.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

10.

Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.

Le Moing V, Thiébaut R, Chêne G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaïed F, Leport C, Raffi F; ANRS CO8 (APROCO/COPILOTE) Study Group.

HIV Med. 2007 Apr;8(3):156-63.

11.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713
12.

Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.

Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):50-7.

PMID:
14501793
14.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
15.

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.

PMID:
16323104
16.

Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.

Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, Lourenço M, Rothschild C, Rouzioux C.

AIDS. 2004 Jan 2;18(1):45-9.

PMID:
15090828
17.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
18.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
19.
20.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

PMID:
16941337

Supplemental Content

Support Center